Drugs / rDEN4delta30
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00919178 | Jul 2009 → May 2010 | dengue shock syndrome | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rDEN4delta30 | “The vaccine candidate in this study is live-attenuated rDEN4delta30, which will target the DEN4 serotype, it is a potential component for a future tetravalent dengue vaccine.” NCT00919178 ↗ |
| Modality | Vaccine | “The vaccine candidate in this study is live-attenuated rDEN4delta30” NCT00919178 ↗ |
| Route | Subcutaneous | “Vaccine will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL.” NCT00919178 ↗ |